{"symbol":"REGN","fiscalQuarter":"Q3-2024","reportDate":"2024-10-31","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2024","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 9.17%","keyNumbers":[{"metric":"EPS","actual":"$12.46","expected":"N/A","surprise":"+23.89%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management noted ongoing challenges in the market.","They emphasized a focus on innovation despite current pressures."],"summary":"Management expressed caution regarding market conditions and highlighted their commitment to research and development. They did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a strong EPS performance, exceeding expectations significantly. However, the stock fell by 9.17% in reaction, likely due to the lack of revenue data and cautious management commentary about market challenges. Investors may be concerned about the company's future performance without clear guidance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2024 earnings: EPS beat by 23.89%. Stock down 9.17%. Full breakdown."}}